These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 29253083)
1. Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer. Schou JV; Larsen FO; Sørensen BS; Abrantes R; Boysen AK; Johansen JS; Jensen BV; Nielsen DL; Spindler KL Ann Oncol; 2018 Mar; 29(3):610-615. PubMed ID: 29253083 [TBL] [Abstract][Full Text] [Related]
2. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience. Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909 [TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of C-Reactive Protein-to-Albumin Ratio with Rectal Cancer Patient Undergoing Chemoradiotherapy Followed by Surgery. Ide S; Toiyama Y; Okugawa Y; Oki S; Yasuda H; Fujikawa H; Yoshiyama S; Hiro J; Kobayashi M; Ohi M; Araki T; Kusunoki M Anticancer Res; 2017 Oct; 37(10):5797-5804. PubMed ID: 28982904 [TBL] [Abstract][Full Text] [Related]
4. Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: Long-Term Outcome. Hess V; Winterhalder R; von Moos R; Widmer L; Stocker P; Jermann M; Herrmann R; Koeberle D Clin Colorectal Cancer; 2017 Sep; 16(3):240-245. PubMed ID: 27687815 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemo-radiotherapy for cT3N0 rectal cancer: any benefit over upfront surgery? A propensity score-matched study. Sorrentino L; Guaglio M; Battaglia L; Bonfanti G; Vitellaro M; Bianchi AC; Milione M; Belli F Int J Colorectal Dis; 2019 Dec; 34(12):2161-2169. PubMed ID: 31741026 [TBL] [Abstract][Full Text] [Related]
6. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer. Tural D; Ozturk M; Selcukbiricik F; Yildiz O; Elicin O; Turna H; Guney S; Ozguroglu M J BUON; 2013; 18(2):385-90. PubMed ID: 23818350 [TBL] [Abstract][Full Text] [Related]
7. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer. Yu J; Li N; Wang X; Ren H; Wang W; Wang S; Song Y; Liu Y; Li Y; Zhou X; Luo A; Liu Z; Jin J Oncotarget; 2016 Sep; 7(39):64233-64243. PubMed ID: 27572313 [TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T; Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067 [TBL] [Abstract][Full Text] [Related]
9. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE). Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356 [TBL] [Abstract][Full Text] [Related]
10. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L; Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473 [TBL] [Abstract][Full Text] [Related]
11. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Tie J; Cohen JD; Wang Y; Li L; Christie M; Simons K; Elsaleh H; Kosmider S; Wong R; Yip D; Lee M; Tran B; Rangiah D; Burge M; Goldstein D; Singh M; Skinner I; Faragher I; Croxford M; Bampton C; Haydon A; Jones IT; S Karapetis C; Price T; Schaefer MJ; Ptak J; Dobbyn L; Silliman N; Kinde I; Tomasetti C; Papadopoulos N; Kinzler K; Volgestein B; Gibbs P Gut; 2019 Apr; 68(4):663-671. PubMed ID: 29420226 [TBL] [Abstract][Full Text] [Related]
12. Clinical Impact of Preoperative Albumin-Globulin Ratio in Patients with Rectal Cancer Treated with Preoperative Chemoradiotherapy. Toiyama Y; Oki S; Okugawa Y; Ide S; Yasuda H; Fujikawa H; Yoshiyama S; Hiro J; Ohi M; Inoue Y; Araki T; Kusunoki M Oncology; 2018; 95(5):270-280. PubMed ID: 29996133 [TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Pretreatment Serum CA199 in Patients with Locally Advanced Rectal Cancer Treated with CRT Followed by TME with Normal Pretreatment Carcinoembryonic Antigen Levels. Huang D; Lin Q; Song J; Xu B Dig Surg; 2021; 38(1):24-29. PubMed ID: 33171467 [TBL] [Abstract][Full Text] [Related]
14. Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial. Vidal J; Casadevall D; Bellosillo B; Pericay C; Garcia-Carbonero R; Losa F; Layos L; Alonso V; Capdevila J; Gallego J; Vera R; Salud A; Martin-Richard M; Nogué M; Cillán E; Maurel J; Faull I; Raymond V; Fernández-Martos C; Montagut C Clin Cancer Res; 2021 May; 27(10):2890-2898. PubMed ID: 33727257 [TBL] [Abstract][Full Text] [Related]
15. Delay to Adjuvant Chemotherapy: Survival and Recurrence in Patients of Rectal Cancer Treated with Neo-adjuvant Chemoradiotherapy and Surgery. Thong DW; Kim J; Naik A; Lu CT; Nolan GJ; Von Papen M J Gastrointest Cancer; 2020 Sep; 51(3):877-886. PubMed ID: 31691086 [TBL] [Abstract][Full Text] [Related]
16. Disease Control, Survival, and Toxicity Outcome After Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Single-Institution Experience. De Felice F; Musio D; Magnante AL; Bulzonetti N; Benevento I; Caiazzo R; Tombolini V Clin Colorectal Cancer; 2016 Jun; 15(2):e17-22. PubMed ID: 26952656 [TBL] [Abstract][Full Text] [Related]
17. Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study. Zhou J; Wang C; Lin G; Xiao Y; Jia W; Xiao G; Liu Q; Wu B; Wu A; Qiu H; Zhang F; Hu K; Xue H; Shen Z; Wang Z; Han J; Niu B; Xu Y; Yu Z; Yang L Clin Cancer Res; 2021 Jan; 27(1):301-310. PubMed ID: 33046514 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Capecitabine (Xeloda) vs. Combination of Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant CRT for Locally Advanced Rectal Cancer. Yaghobi Joybari A; Azadeh P; Babaei S; Hosseini Kamal F Pathol Oncol Res; 2019 Oct; 25(4):1599-1605. PubMed ID: 30712194 [TBL] [Abstract][Full Text] [Related]
19. Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series. Sastre J; Serrano JJ; Fernández C; Ramirez C; Ortega L; García-Paredes B; Corona J; Alfonso R; Córdoba S; Díaz-Rubio E Clin Colorectal Cancer; 2016 Jun; 15(2):128-34. PubMed ID: 26385572 [TBL] [Abstract][Full Text] [Related]
20. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation. Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]